Tuebingen, Germany

Andreas Moritz

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 5.1

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Andreas Moritz

Introduction

Andreas Moritz is a notable inventor based in Tuebingen, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of antigen binding proteins and methods for peptide-MHC affinity screening. With a total of 2 patents, his work has implications for medical applications and cancer prevention.

Latest Patents

One of his latest patents is focused on antigen binding proteins specifically binding to a CT45 antigenic peptide. This invention provides a detailed description of the antigen binding protein, which includes a first polypeptide with a variable domain and a second polypeptide with additional variable domains. The patent also covers nucleic acids encoding these proteins, vectors, recombinant cells, and pharmaceutical compositions for medical use.

Another significant patent by Moritz relates to a method for high throughput peptide-MHC affinity screening for TCR ligands. This method involves a stabilized peptide-MHC molecule complex and outlines the uses of this method in developing polypeptides, pharmaceutical compositions, and vaccines aimed at cancer prevention.

Career Highlights

Throughout his career, Andreas Moritz has worked with prominent companies in the biotechnology sector, including Immatics Biotechnologies GmbH and Emmatics Biotech. His experience in these organizations has contributed to his expertise in the field and the successful development of his patents.

Collaborations

Moritz has collaborated with several professionals in his field, including Dominik Maurer and Sebastian Bunk. These collaborations have likely enhanced his research and development efforts, leading to innovative solutions in biotechnology.

Conclusion

Andreas Moritz is a distinguished inventor whose work in antigen binding proteins and peptide-MHC affinity screening has the potential to advance medical science and cancer treatment. His contributions reflect the importance of innovation in biotechnology and its impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…